Startseite Corrigendum to: Formulation of a 3-months Stability Oral Viscous Budesonide Gel and Development of an Indicating Stability HPLC Method
Artikel Öffentlich zugänglich

Corrigendum to: Formulation of a 3-months Stability Oral Viscous Budesonide Gel and Development of an Indicating Stability HPLC Method

Dieses Erratum berichtigt die Onlineversion des folgenden Artikels: https://doi.org/10.1515/pthp-2018-0005
  • Mathilde Bonnet EMAIL logo , Marine Dermu , Clara Roessle , Marc Bellaiche , Tarik Abarou , Véronique Vasseur , Samira Benakouche und Thomas Storme
Veröffentlicht/Copyright: 11. April 2019
Veröffentlichen auch Sie bei De Gruyter Brill

Corrigendum to: Mathilde Bonnet, Marine Dermu, Clara Roessle, Marc Bellaiche, Tarik Abarou, Véronique Vasseur, Samira Benakouche and Thomas Storme. Formulation of a 3-months Stability Oral Viscous Budesonide Gel and Development of an Indicating Stability HPLC Method. Pharmaceutical Technology in Hospital Pharmacy. Volume 3, Issue 2, pages 91–99. (DOI https://doi.org/10.1515/pthp-2018-0005)

In Table 1, on page 94, the formulation was based on the original formula published by Eyal Zur, compounding pharmacist and consultant from Israel, in the International Journal of Pharmaceutical Coupounding in 2012. [1]

[1] Zur, E. 2012. Eosinophilic esophagitis: treatment with oral viscous budesonide. Int. J. Pharm. Compd. 16: 288–293.

Received: 2019-02-14
Revised: 2019-03-21
Accepted: 2019-03-21
Published Online: 2019-04-11
Published in Print: 2019-05-02

© 2019 Walter de Gruyter GmbH, Berlin/Boston

Heruntergeladen am 9.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/pthp-2018-9005/html
Button zum nach oben scrollen